A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Histologically or cytologically documented, incurable, or metastatic solid malignancy that has progressed on or failed to respond to regimens or therapies known to provide clinical benefit Specific to Arm A: * For patients undergoing optional or mandatory exploratory MRI, at least one tumor lesion that represents a liver, fixed peritoneal, neck, extremity, or pelvic lesion measuring \>/= 3 to 10 cm (for liver lesions) or \>= 2 to 10 cm (for all other lesion locations) to be used for MRI Specific to Arm B: * Maximum of two prior chemotherapy regimens for metastatic disease Exclusion Criteria: * Anti-cancer therapy within 3 weeks prior to initiation of study treatment * Patients who had to discontinue prior bevacizumab therapy due to intolerable toxicity * Leptomeningeal disease * Active infection or autoimmune disease * Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, or cirrhosis * Known primary central nervous system (CNS) malignancy or untreated or active CNS metastases * Inadequately controlled hypertension; history of hypertensive crisis or encephalopathy; congestive heart failure (New York Heart Association Class II or greater); history of myocardial infarction or unstable angina within 6 months prior to initiation of study treatment * History of hemoptysis; evidence of bleeding diathesis or significant coagulopathy * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment * Serious, non-healing wound, active gastrointestinal ulcer, or untreated bone fracture Specific to Arm B: * Known significant hypersensitivity to paclitaxel or other drugs using the vehicle cremophor * Previous intolerance to paclitaxel * Grade \>= 2 sensory neuropathy